These discounted versions of popular weight-loss drugs are going away: What to know USA TODAY
Month: March 2025
What’s Next for Semaglutide? Beyond Diabetes and Weight Loss – News-Medical.Net
What's Next for Semaglutide? Beyond Diabetes and Weight Loss News-Medical.Net
The weight-loss drugs being tested in 2025: will they beat Ozempic? – Nature.com
The weight-loss drugs being tested in 2025: will they beat Ozempic? Nature.com
Weight loss drugs may become harder to get. What does that mean for patients? – WBUR News
Weight loss drugs may become harder to get. What does that mean for patients? WBUR News
As diabetes drives up Kentuckians’ use of weight-loss drugs, worries arise about unintended effects – LINK nky
As diabetes drives up Kentuckians’ use of weight-loss drugs, worries arise about unintended effects LINK nky
CHMP recommends AbbVie’s Rinvoq be approved for adult GCA
The CHMP has recommended the approval of AbbVie’s upadacitinib (Rinvoq) for treating adults with giant cell…
Rare disease treatments skipping UK patients largely due to costs, survey shows
A survey has shown that pharma companies have low confidence their rare disease medicines can launch…
Medigene and EpimAb to develop T cell engagers for solid tumours
Medigene and EpimAb Biotherapeutics have signed a co-development agreement involving T cell receptor (TCR)-guided T cell…
Why pharma is still far from a treatment for galactosemia
With issues in therapy delivery and a barren trial landscape, short-term chances for a commercial galactosemia…
FDA accepts Sobi’s Gamifant application for HLH/MAS treatment
The FDA has accepted Sobi’s sBLA for Gamifant for haemophagocytic lymphohistiocytosis (HLH)/MAS associated with Still’s disease.